Akorn expects its acquisition of Hi-Tech to close early in the second quarter
MLex Summary: Pharmaceutical company Akorn expects its planned $640 million acquisition of Nasdaq-listed rival Hi-Tech Pharmacal to close early in the second quarter of this year, Akorn said in a filing with the...To view the full article, register now.
Already a subscriber? Click here to view full article